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Abstract
Background: Immune cell trafficking into the CNS and other tissues plays important roles in health and disease.
Rapid quantitative methods are not available that could be used to study many of the dynamic aspects of immune
cell-tissue interactions.
Methods: We used pharmacokinetics and modeling to quantify and characterize the trafficking of radioactively
labeled lymphocytes into brain and peripheral tissues. We used variance from two-way ANOVAs with 2 × 2
experimental designs to model the relative influences of lymphocytes and target tissues in trafficking.
Results: We found that in male CD-1 mice, about 1 in 5,000 intravenously injected lymphocytes entered each gram
of brain. Uptake by brain was 2 to 3 times higher in naïve SJL females, but uptake by spleen and clearance from
blood was lower, demonstrating a dichotomy in immune cell distribution. Treatment of CD-1 mice with
lipopolysaccharide (LPS) increased immune cell uptake into brain but decreased uptake by spleen and axillary
nodes.
Conclusions: Differences in brain uptake and in uptake by spleen between SJL and CD-1 mice were primarily
determined by lymphocytes, whereas differences in uptake with LPS were primarily determined by lymphocytes for
the brain but by the tissues for the spleen and the axillary lymph node. These results show that immune cells
normally enter the CNS and that tissues and immune cells interact in ways that can be quantified by
pharmacokinetic models.
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Background
The central nervous system (CNS) is an immune-
privileged tissue. Its invasion by immune cells during
autoimmune diseases, such as multiple sclerosis, under-
lies much of the pathology of those diseases and is key
to their treatment [1]. Immune cell invasion of the CNS
is increasingly viewed as important to the development
and progression of a wide range of diseases including
neuroAIDS [2,3], trauma to the CNS [4], stroke [5], epi-
lepsy [6], and neurodegenerative diseases [7]. More
recently, the CNS has emerged as an immune-active tis-
sue under normal physiologic conditions, rather than
merely in disease states [8,9]. Similarly, it is now widely
accepted that immune cells routinely migrate into the
CNS in small but undetermined amounts at a low but
undetermined rate [10]. The possibility that immune cell
trafficking into the CNS may occur normally is sug-
gested by the finding that immune cells readily cross
brain endothelial cells when studied with in vitro models
of the blood–brain barrier (BBB) [11]. The development
of progressive multifocal leukoencephalopathy in
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patients treated with antibodies that prevent or retard
immune cell entry into the CNS has suggested that the
CNS may normally be under immune surveillance from
cells trafficking into the CNS [12].
The degree to which immune cells normally cross the
BBB is difficult to address with the methods classically
employed. Almost all in vivo studies of immune cell traf-
ficking into the CNS have used models that activate the
immune system in imitation of a disease state, as exem-
plified by induction of experimental allergic encephalitis
in the study of multiple sclerosis [13,14], or invoke neu-
roimmune responses with cytokines, lipopolysaccharide
(LPS), or viruses [2,3,15,16]. Classic studies have demon-
strated that immune cell entry into the CNS involves an
intimate cross talk between the brain endothelial cells
comprising the BBB and the circulating immune cells.
The difficulty in quantifying immune cell uptake, how-
ever, makes it difficult to determine the temporal course
of uptake, the relative distribution of immune cells
among tissues, and whether it is the immune cell or the
target tissue that initiates or dominates trafficking. Here,
we adapt pharmacokinetic techniques and modeling to
quantify lymphocyte uptake and distribution patterns.
With these methods, we were able to quantify the rate at
which lymphocytes were taken up by brain and periph-
eral tissues, clearance rates from the circulation, the ef-
fect of genetic strain and activation of the innate
immune system on lymphocyte distribution, and the
relative contributions made by lymphocytes and target
tissues in that distribution.
Methods
All animals were studied according to approved proto-
cols that conformed to the NIH Guide for the Care and
Use of Laboratory Animals and approved by the local
animal use committee (John Cochran VA, St. Louis,
MO. USA). Two strains of outbred mice, male CD-1
from our in-house colony (VA, St. Louis) and female
SJL/J mice (Jackson Laboratories, Bar Harbor, ME), 8 to
12 weeks of age, were used to harvest lymphocytes and
perform the in vivo injection studies.
Lymphocyte harvest
Cervical-node mixed lymphocytes were harvested from
two or three SJL/J or CD-1 mice, which were anesthe-
tized with an intraperitoneal (i.p.) injection of 40% ethyl
carbamate. Prior to harvesting the lymph nodes, the vas-
cular space of the head and neck was washed free of
blood. Each mouse was placed in a supine position and
the skin removed from the neck to expose the right and
left jugular veins. The thorax was opened by cutting
through the sternum from the epigastric region of the
abdomen to the sternal notch. Both jugular veins were
severed. The descending thoracic aorta was clamped
with a hemostat. The head and neck were then perfused
with 20 ml of lactated Ringer’s solution (LR) injected
into the left ventricle of the heart over a one minute
interval, using a 20 ml syringe with a 20 g needle.
Four cervical lymph nodes were then dissected clean
and harvested from each mouse and placed in a petri
dish with normal saline (NS) at room temperature. For-
ceps were used to tease apart the nodal tissue to release
lymphocytes into the NS solution, and the cell suspen-
sion placed in a 12 × 75 mm polypropylene tube. The
cells were centrifuged at 300 rpm for 3 min to remove
tissue fragments. The supernatant containing the lym-
phocytes was transferred to a clean tube and centrifuged
at 1,000 rpm for 10 min to pellet the lymphocytes. The
supernatant was discarded and the cells washed twice
with 1 ml 0.25 M phosphate buffer at pH 7.5 (PB) to re-
move the NS. The cells were then resuspended in 200 μl
PB and radioactively labeled as described later.
Lymphocyte iodination
To iodinate the harvested lymphocytes, two IodoBeads
(Pierce, Inc., Rockford, IL) were washed twice with 500 μl
PB for 30 s each wash, and placed in a 12 × 75 mm glass
tube with 200 μl PB. A total of 2 mCi 131I (Perkin Elmer,
Shelton, CT) was added and incubated at room
temperature for 5 min. The cells were resuspended by
lightly vortexing, 200 μl of the suspension was added to
the iodination material, and the mixture was incubated at
room temperature for 20 min. The iodination mixture was
vortexed to resuspend the cells, and all liquid was removed
from the reaction tube to a clean 12 × 75 mm glass tube.
To remove the free iodine, the iodination material was
centrifuged at 1,000 rpm for 10 min to pellet 131I-lym-
phocytes (I-lymphocytes). The supernatant was dis-
carded and the 131I-lymphocytes washed at least three
times with 500 μl of lactated Ringer’s solution containing
1% bovine serum albumin (LR-BSA). The 131I-lympho-
cytes were resuspended in 200 μl of LR-BSA and
counted on a standard hemocytometer. To determine
the percentage of 131I incorporated, a 15 μl aliquot of
the 131I-lymphocyte suspension was centrifuged at
20,000g for 20 min, and the amount of radioactivity in
the pellet and supernatant counted in a gamma counter
(Wallac, Inc., Gaithersburg, MD). The 131I-lymphocytes
typically required three washings with LR-BSA to re-
move free 131I and had an incorporation ≥90%. This iod-
ination procedure resulted in a mean specific activity of
53.3 ± 10.97 cpm/lymphocyte (range 19.4 to 94 cpm/
lymphocyte) and a mean cell count of 8.9 × 104 ± 2.1 ×
104 cells/0.1 ml (range 2.5 × 104 to 18 × 104 cells/0.1
ml) with the total level of radioactivity being 42,177 ±
10,914 cpm/μl (range 12,400 to 87,240 cpm/μl). There
were no apparent differences in the iodination results
between the CD-1 and SJL/J lymphocytes.
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In vivo 131I-lymphocyte injection studies
These studies were used to determine the clearance and
distribution of 131I-lymphocytes after their intravenous
(i.v.) injection. Mice (n = 7/time point) were anesthe-
tized with 40% ethyl carbamate and the skin excised
from the neck between the sternal notch and the chin.
The cervical fat pad was pulled back to expose the left
jugular vein for i.v. injection. The 131I-lymphocytes were
injected into the left jugular vein in a volume of 0.2 ml
of LR-BSA at a concentration of 150,000 cpm/mouse.
The 131I-lymphocyte solution was mixed vigorously prior
to filling the syringe to resuspend the cells. An injection
check of 0.2 ml, representing the total cpm injected into
each mouse, was also placed into a 12 × 75 mm tube
and the level of radioactivity determined. At post-
injection study times of 5, 15, 30, 90, or 150 min, a mid-
line laparotomy was performed to expose the abdominal
aorta. The aorta was severed and blood collected in a
preweighed 0.6 ml microcentrifuge tube. The tube was
weighed again to determine the amount of blood col-
lected and the blood was allowed to clot at room
temperature, and then centrifuged at 20,000g for 20 min.
The serum was then removed and its volume deter-
mined and the remaining volume of the red blood cell
(RBC) pellet calculated. The radioactivity representing
the 131I-lymphocytes in the pellet was determined in the
gamma counter. Results are expressed as cpm/μl of RBC
pellet or as the percentage of the injected dose per ml of
pellet (%Inj/ml).
Immediately following the blood collection, a thoracot-
omy was performed with a midline incision through the
sternum to the sternal notch. Both jugular veins were
severed, and the descending thoracic aorta clamped.
Cardiac perfusion with 20 ml of LR was accomplished as
described, to wash out all blood components from the
vascular space of the head and neck. The cervical nodes,
axillary nodes, and spleen were collected and weighed.
The mouse was then decapitated, the parietal skull
removed, and the brain exclusive of the pineal body and
pituitary, removed and weighed. The brain was placed in
12 × 75 mm polytubes with 1 ml of LR-BSA. The brain
and peripheral tissues were centrifuged at 4,800 rpm for
10 minutes to pellet the tissue into the bottom of the
tube, then the level of radioactivity determined with a
gamma counter.
Each brain was homogenized using a Polytron (Brink-
mann Instruments, Westbury, NY) with a 7 mm probe
operated at setting 20 for 15 s. The homogenate was
placed in a microfuge tube and centrifuged at 20,000g
for 20 minutes to pellet all cellular material. The super-
natant and pellet were separated and the radioactivity in
each determined with the gamma counter.
To verify that the 131I-lymphocytes were separated
into the RBC and the brain pellets during centrifugation,
processing controls (n = 2) were performed in which
131I-lymphocytes (150,000 cpm) were added to arterial
blood or to whole brain that had the vascular contents
washed out; these samples were from normal CD-1
mice. These were then processed as above and the level
of radioactivity determined in the blood RBC pellet and
serum and the brain pellet and supernatant. The RBC
pellet contained 87% of the total level of radioactivity,
while the brain pellet contained 89% of the total level of
radioactivity.
Uptake by brain and other tissues were quantified by
expressing results in two ways. For the brain or tissue/
RBC pellet ratios, the percentage of injected dose taken
up per g of tissue was calculated. The former is inde-
pendent of clearance from blood and the latter is useful
for calculating global effects on tissue uptake. For the
brain/RBC ratios and tissue/RBC ratios, the levels of
radioactivity in the brain pellet and the RBC pellet were
used to calculate
Brain=RBC ratio ¼ cpm=g of brain pelletð Þ½
ðcpm=μl of RBC pelletÞ
ð1Þ
in units of μl/g. Similarly, the tissue/RBC ratios were cal-
culated for spleen, cervical nodes, and axillary nodes.
These were plotted against time to determine the tem-
poral pattern of 131I-lymphocyte uptake by the brain or
peripheral tissues.
For the percentage of injected dose taken up by the
brain, the percentage of the i.v. injected dose of 131I-lym-
phocytes taken up by a gram of brain (%Inj/g) was calcu-
lated from the equation
%Inj=g ¼ tissue cpm=Injð Þ=tissue wt:½   100 ð2Þ
where tissue cpm is the level of radioactivity measured
in the specific tissue, and tissue wt. is the weight in
grams of the specific tissue.
Clearance from blood
The percentage of the intravenously injected dose of
131I-lymphocytes per ml of arterial blood (%Inj/ml) was
calculated from the equation:
%Inj=ml ¼ 100 Cp=Injð Þ ð3Þ
where Cp is the cpm/ml of the RBC pellet and Inj is the
total cpm injected i.v. The log %Inj/ml was plotted
against time and the inverse of the slope of the linear
portion multiplied by 0.301 to obtain the half-time clear-
ance. The inverse of the antilog of the intercept was
multiplied by 100 to give the initial volume of distribu-
tion (Vd).
To examine regional brain uptake, this study com-
pared the relative permeability of various brain regions
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to 131I-lymphocytes. Blood and brains were collected 30
min after injection. The brain was dissected into 11
brain regions (olfactory bulb, frontal cortex, parietal cor-
tex, occipital cortex, striatum, hippocampus, thalamus,
hypothalamus, cerebellum, midbrain, pons-medulla)
after the method of Glowinski and Iversen [17]. Regions
were weighed and their levels of radioactivity deter-
mined. Values for whole brain were calculated based on
the summations of the regional brain weights and the
regional radioactivity levels of the brain regions.
Autoradiography and immunohistochemistry of tissues
These studies were performed to confirm that radio-
activity taken up by brain was associated with lympho-
cytes. The 131I-lymphocytes were injected into the left
jugular vein in a volume of 0.2 ml of LR-BSA at a con-
centration of 34,000 cpm/0.2 ml and 18 × 104 cells/0.2
ml. Five minutes post-injection, cardiac washout was
performed as described. Four cervical nodes were
removed, placed in 1 ml of PB, and then teased apart
with forceps. The cellular suspension was centrifuged at
300 rpm for 10 min to remove tissue particles. The
lymphocyte-containing supernatant was then centrifuged
at 1,000g for 15 minutes to pellet the 131I-lymphocytes.
The pellet was resuspended in 100 μl fresh LR-BSA,
then slide smears prepared using 15 μl of I-lymphocyte
suspension on each slide. The slides were dried over-
night, heat fixed at 60°C for 20 min then stored at 4°C
until stained.
In a companion study to visualize 131I-lymphocytes in
the brain parenchyma, CD-1 or SJL mice were anesthe-
tized and prepared for i.v. injection, as before. 131I-lym-
phocytes were i.v. injected at a concentration of about
4.5 × 106 CPM/0.2 ml and 2,000 × 104 cells/0.2 ml, with
CD-1 mice receiving 131I-lymphocytes from CD-1 mice
and SJL mice receiving 131I-lymphocytes from SJL mice.
Thirty minutes after i.v. injection, the thorax was opened
and cardiac washout was performed to clear the brain
vasculature of blood. The mice were decapitated, the
brain removed and the central region isolated by making
two coronal cuts, one anterior to the hypothalamus, and
a second cut posterior to the occipital cortex. This cen-
tral brain region was then flash frozen in isopentane
(Sigma Chemical, St. Louis, MO) and dry ice. The frozen
specimen was mounted on a cryostat chuck at −16°C
using OTC compound. Following a 2 hour equilibration
period, 20 μm sections were cut using a Reichert-Jung
Cryocut 1800 microtome (Leica Microsystems Inc., Ban-
nockburn, IL). Every four to ten sections were mounted
on glass slides, and dried at room temperature to adhere
sections to the slides; the slides were stored at −70°C
until stained. Slides of the cervical-node lymphocyte
smear or brain sections were brought to room
temperature and allowed to dry. The slides were fixed in
acetone: alcohol, 75:25, for 5 min, then washed in phos-
phate buffered saline (PBS). The sections were then
blocked in 5% BSA in PBS for 30 minutes and washed in
PBS; then endogenous peroxidase was blocked for 5 min
using PBS with 0.3% H2O2 and 0.3% BSA. After washing
in PBS, the sections were incubated with primary puri-
fied rat anti-mouse CD45 (leukocyte common antigen,
Ly-5) antibody, CD45, 1:50 dilution (BD Pharmingen,
San Jose, CA) in PBS overnight at 4°C. Slides were then
washed with PBS and incubated for 30 min at room
temperature with 1:200 dilution of biotinylated anti-rat
IgG (Vector Laboratories, Burlingame, CA). Slides were
washed with PBS and incubated with Vectastain ABC
reagent (Vector Laboratories, Burlingame, CA) for 30
min. Slides were washed in PBS and stained with DAB
solution (Vector Laboratories, Burlingame, CA) with
nickel solution for 8 min. The reaction was stopped with
PBS, and the slides rinsed well with water, then counter-
stained with hematoxylin (Sigma Chemical, St. Louis,
MO) for 30 s, rinsed with water and allowed to dry at
room temperature.
Slides for brain and lymph nodes were then processed
for autoradiography by dipping each slide in a 50% solu-
tion of Kodak Emulsion, Type NTB (Kodak, Rochester,
NY) at 45°C for 10 s, then allowed to dry at room
temperature in the dark. The slides were then sealed in
light-tight boxes and stored at 4°C for 3 days. Following
a 3 day exposure time, slides were processed using
Kodak D-19 developer and fixer, dehydrated with graded
alcohols and xylene, and coverslipped. Autoradiographic
slides were examined using a Nikon Eclipse 80i micro-
scope (Nikon Instruments Inc., Melville, NY), and
photomicrographs were taken using a Photometrics Cool
Snap cf camera (Roper Scientific Photometrics, Tucson,
AZ) and MetaMorph v 6.1 software (Universal Imaging
Corp., Downingtown, PA).
Capillary depletion
This method was used to distinguish full penetration of
the capillary wall with entry into the brain parenchymal
space from association with the luminal surface of the
capillary. In male CD-1 mice (n = 2), the relative distri-
bution of 131I-lymphocytes between the cerebral cortex
parenchyma and the capillaries was determined by the
method of Triguero et al. [18] as modified for mice by
Gutierrez et al. [19]. Following anesthesia, the left jugu-
lar vein was exposed as described above. Using a 1 ml
syringe, 0.2 ml of LR-BSA containing 1 × 106 cpm of
131I-lymphocytes was injected into the jugular vein.
Thirty minutes later, the abdomen was opened and
blood collected from the abdominal aorta. The RBC pel-
let was collected as described previously and the level of
radioactivity determined. The thorax was opened, the
thoracic descending aorta clamped, the left and right
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jugular veins severed, and the brain flushed of its intra-
vascular contents by injecting 20 ml of LR solution over
1 minute into the left ventricle of the heart. The mouse
was decapitated and the brain harvested as described
above. The cerebral cortex was isolated, weighed, and
placed in ice-cold physiological buffer (10 mM HEPES,
141 mM NaCl2, 4 mM KCL, 2.8 mM CaCl2, 1 mM
MgSO4, 1 mM NaH2 PO4, and 10 mM D-glucose,
adjusted to pH 7.4). The cortex was then homogenized
in 0.8 ml of physiological buffer using a glass tissue
grinder (ten vertical strokes). A dextran solution, 1.6 ml
of a 26% solution in the physiological buffer, was added
to the homogenate, mixed vigorously, and homogenized
with three additional vertical strokes. The homogenate
was centrifuged at 5,400g for 15 minutes at 4°C in a
swing bucket rotor. The pellet containing the brain vas-
culature and the supernatant consisting of the brain par-
enchyma were carefully separated and the radioactivity
of each component determined with a gamma counter.
The parenchyma/pellet and capillary/pellet ratios (μl/g)
were calculated by the equation:
Fr=pellet ¼ cpm Frð Þ= wt:ð Þ cpm=μl pelletð Þ ð4Þ
where cpm Fr is the cpm in either the parenchyma or
supernatant fraction, wt. is the weight of the cortex, and
cpm/μl pellet is the level of cpm in a microliter of RBC
pellet.
To confirm that capillary depletion was an appropriate
method for lymphocytes, processing controls for capil-
lary depletion (n = 2) were performed by adding 1.5 ×
105 CPM 131I-lymphocytes to a tube containing arterial
blood. This blood was then added to a brain in which
the vascular contents had been removed by washout
with LR, as described previously. The blood and brain
were then processed, as described previously, for capil-
lary depletion and the level of radioactivity in the pellets
and supernatants determined in the gamma counter.
The ratios (Fr/pellet) for parenchyma (0.57 ± 0.14) and
capillary (0.82 ± 0.22) were not statistically different
from each other (n = 3/group, P = 0.3758) with about
41% of the lymphocytes segregating with the paren-
chyma fraction.
Lymphocyte uptake by CD-1 and SJL/J mice
This study compared these two strains for 131I-lympho-
cyte clearance from blood, brain distribution, and uptake
by peripheral tissues. Lymphocytes from either CD-1 or
SJL/J mice, n = 2 or 3 per strain, were harvested and
iodinated as described, and i.v. injection studies per-
formed in both CD-1 and SJL/J mice. A 2 × 2 design
was employed, where iodinated lymphocytes from CD-1
mice were injected into CD-1 or SJL/J mice, n = 7/strain,
and iodinated lymphocytes from SJL/J mice were
injected into CD-1 or SJL/J mice, n = 7/strain. Blood
from the abdominal aorta was collected 30 minutes after
the injection, and washout performed as described previ-
ously. The cervical and axillary nodes, the spleen, and
the brain were collected. The number and weight of
each type of lymph node was recorded, and the weight
per node calculated. The spleen and whole brain were
weighed. Blood and tissues were processed as described
previously and the level of radioactivity in each mea-
sured with a gamma counter. The tissue/RBC ratios and
clearance from blood (%Inj/ml) were determined as
described previously.
The effect of activation of the innate immune system
with LPS on 131I-lymphocyte clearance, uptake, and dis-
tribution in male CD-1 mice was studied. CD-1 mice
(n = 3) were treated with either i.p. injections of LPS or
0.25 M phosphate buffer, pH 7.5 (PB). The LPS (Sigma
Chemical Co., St. Louis, MO) was prepared from
Salmonella typhimurium and administered to each
mouse in a dosage of 3 mg/kg at time 0, 6 h, and 24 h.
Four hours after the 24 h i.p. LPS or PB injection, the
mice were anesthetized, the vasculature of the head and
neck washed free of blood, and lymphocytes harvested
and iodinated as described previously.
Other CD-1 mice were treated with i.p. injections of
either LPS or PB at time 0, 6 h and 24 h. Four hours
after the 24 h i.p., LPS or PB injection, a 2 × 2 designed
study was accomplished, where 131I-lymphocytes from
LPS-treated mice were injected into LPS- (n = 7) or PB-
(n = 6) treated mice, and 131I-lymphocytes from PB-
treated mice were injected into LPS- (n = 5) or PB- (n =
7) treated mice. The mice were anesthetized, the jugular
veins exposed, and the 131I-lymphocytes injected into
the left jugular vein in a volume of 0.2 ml of LR-BSA at
a concentration of 150,000 cpm/mouse. An injection
check of 0.2 ml was placed into a 12 × 75 mm tube and
the level of radioactivity determined. At the post-
injection study time of 30 min, a midline laparotomy
was performed, the abdominal aorta severed and blood
collected in a 0.6 ml microcentrifuge tube. The vascula-
ture of the head and neck was washed free of blood and
the cervical nodes, axillary nodes, spleen, and whole
brain were collected as previously described. The blood
and tissues were processed as described previously and
the level of radioactivity determined with a gamma
counter. The tissue/RBC ratios and %Inj/ml were calcu-
lated as previously described.
Statistical analysis
Statistical calculations were performed with Prism 5.0
software (GraphPad Software, San Diego, CA). Means
are reported with their standard errors and the number
of animals (n) per group. Two group comparisons were
performed using Student’s two-tailed, unpaired t test
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with comparisons considered significant at the P < 0.05
level. For time curve comparisons, a two-way analysis of
variance (ANOVA) was used to compare the independ-
ent variables followed by the Bonferroni post-test to
compare values at individual times. For the 2 × 2
designs, a two-way ANOVA was used to compare the
two independent variables (the source of the cells (Cells)
and the mouse into which they were injected (Mouse))
followed by one-way ANOVA and Newman-Keuls post-
test to compare the four values with each other.
Results
The uptake of 131I-lymphocytes by the brain in CD-1
and SJL mice is shown in Figure 1. These results show
that 131I-lymphocytes were taken up by the brains of
both CD-1 and SJL mice. The top panel compares
results expressed as %Inj/g (n = 4/group). A two-way
ANOVA showed an effect of mouse strain (F(1, 30) =
27.0, P < 0.0001), but not of time or interaction. The
Bonferroni post-test compared CD-1 and SJL mouse
strains at each of the various times and found statistical
differences at 15 min (P < 0.05) and 150 min (P < 0.05).
The lower panel compares the results expressed as
brain/RBC pellet ratios. The two-way ANOVA showed
an effect of strain (F(1,30) = 34.9, P < 0.0001), time
(F(4,30) = 5.52, P < 0.005)), and interaction (F(4,30) =
2.96, P < 0.05). The Bonferroni post-test comparing CD-
1 and SJL mice at each of the various times found a stat-
istical difference at 15 min (P < 0.001). These results
show that lymphocytes were taken up by the brain and
rapidly achieved steady state, and that lymphocyte up-
take by brain was greater for SJL mice than for CD-1
mice.
Capillary depletion was performed in male CD-1 mice
to determine whether the brain retention of 131I-lym-
phocytes found in Figure 1 was because they crossed the
BBB completely to enter the parenchyma of the brain or
were merely retained by brain endothelial cells. Vascular
washout was first performed 30 min after the i.v. injec-
tion of the 131I-lymphocytes, a procedure that removes
cells and substances loosely bound to the luminal sur-
face of the brain’s capillary bed [20]. After that, the brain
was prepared as outlined previously to produce paren-
chymal and capillary fractions. The parenchyma/RBC
ratio was determined to be 28.5 ± 1.4 μl/g, which was
significantly higher than the capillary/RBC ratio of 6.7 ±
2.3, n = 2 μl/g, P = 0.0153. This shows that 81% (100
(28.5)/(28.5 + 6.7) = 81) of the 131I-lymphocytes taken
up by the brain had crossed the capillary wall of the BBB
completely and had entered the brain parenchyma.
Figure 2 (upper left panel) shows the log(%Inj/ml) of
131I-lymphocytes in CD-1 and SJL/J mice at 5 to 150
min after i.v. injection. In CD-1 mice, the 131I-lympho-
cytes were cleared from blood with time, as shown by a
significant relation between log(%Inj/ml) and time, r =
0.577, n = 19, P = 0.0097. The half-time clearance rate
from blood for these 131I-lymphocytes was calculated to
be 171 min. In SJL/J mice, the level of 131I-lymphocytes
in blood was constant, excepting for the first time point,
suggesting that a steady state between entry and exit of
the circulation was quickly established. The Vd for both
strains was about 32 ml, demonstrating a large volume
of distribution or significant tissue sequestration of the
131I-lymphocytes. Calculations of %Inj/g are dependent
on %Inj/ml and so are influenced by differences in clear-
ance of 131I-lymphocytes. Therefore, subsequent analyses
comparing the strains were conducted using tissue/RBC
ratios, which are less influenced by clearance.
Figure 2 compares CD-1 and SJL tissue/RBC ratios for
cervical lymph nodes (upper right panel, no statistically
significant differences), axillary nodes (lower left panel),
and spleen (lower right panel). For cervical nodes, a
Figure 1 Uptake over time of 131I-lymphocytes into brain of
CD-1 male and SJL female mice. Upper panel expresses results as
%Inj/g of brain tissue and lower panel shows results expressed as
brain/RBC ratios. Uptake by SJL mice was 2 to 3 times greater than
in CD-1 mice.
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two-way ANOVA showed an effect of time (F(4,30)
= 6.40, P < 0.001), but not strain or interaction; the
Bonferroni post-test found no differences between
strains at any time. The two-way ANOVA for axillary
nodes found an effect for time (F(4,30) = 7.90, P <
0.001)), but no effect for strain or interaction; the Bon-
ferroni post-test found a difference between CD-1 and
SJL at 30 min. The two-way ANOVA for spleen found
differences for time ((F4,30) = 7.93, P < 0.001), strain (F
(1,30) = 81.3, P < 0.0001), and interaction (F(4,30) =
4.17, P < 0.01); the Bonferroni post-test showed differ-
ences between SJL and CD-1 at 15 min (P < 0.001), 30
min (P < 0.001), 90 min (P < 0.01), and 150 min (P <
0.001). These results demonstrate that spleen, brain, and
clearance from blood, but not cervical or axillary nodes,
showed a difference between the two strains of mice.
These results also show tissue-dependent differential
effects of mouse strain in that CD-1 mice, by compari-
son with SJL mice, had less uptake into brain but more
uptake into spleen.
Cervical node, axillary node, and spleen weights from
CD-1 and SJL/J mice were compared. The wet weights of
nodes of SJL/J mice were found to be significantly greater
than those from CD-1 mice (cervical node: CD-1 = 5.2 ±
0.4 mg, SJL/J = 11.9 ± 1.4 mg, n = 14, P < 0.001; axillary
node: CD-1 = 5.2 ± 0.7 mg, SJL/J = 8.3 ± 1.0 mg, n = 14,
P = 0.016). The spleen also weighed more in the SJL: 179
± 12.4 mg vs. 123 ± 8.7 mg, P < 0.01.
To determine whether the radioactivity in our samples
represented 131I-lymphocytes, we performed both auto-
radiography and immunohistochemistry on brain and
lymph node tissue from CD-1 and SJL mice. Figure 3
shows the results of staining labeled cells with CD45 anti-
body. As a control and reference, panels A and B show
Figure 2 Comparison between CD-1 males and SJL females of clearance from blood and uptake by immune tissues of
131I-lymphocytes. Upper left panel shows clearance of 131I-lymphocytes from the circulation. The half-time clearance for CD-1 mice was 171 min,
but clearance was not measurable for SJL mice. Upper right panel shows that uptake of 131I-lymphocytes into cervical nodes was high in both
SJL and CD-1 mice and did not differ between the strains. Lower left panel showed high uptake of 131I-lymphocytes by axillary nodes was similar
between SJL and CD-1 mice except for the 30 min time point when CD-1 mice had a higher uptake. Lower right panel shows that spleen uptake
was the highest of all the tissues examined and that uptake by CD-1 mice was about 2 to 3 times higher than by SJL mice.
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Figure 3 Immunohistochemistry and autoradiography of 131I-lymphocytes. Cervical lymph node lymphocytes from SJL or CD-1 mice were
radioactively labeled and injected intravenously into the autologous strain. After 30 min, cervical nodes or brain tissue were harvested, processed,
and stained for CD45. Panel A shows 131I-lymphocyte preparation of cervical lymph node lymphocytes obtained from SJL female mice stained for
CD45. Panel B shows stained 131I-lymphocytes prepared from the cervical lymph nodes of CD-1 males. Panels C and D show CD-1 cervical lymph
node cells 30 min after the i.v. injection of 131I-lymphocytes. Panel E shows stained 131I-lymphocyte in cortex from SJL mouse. Panel F shows
stained 131I-lymphocyte from hindbrain in SJL mouse. Panels G and H show CD45 stained 131I-lymphocytes from occipital cortex of CD-1 mice. All
magnifications are at 40×.
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purified 131I-lymphocytes prior to i.v. injection. Panels C
and D show the cervical lymph node smear from CD-1
mice. Panels E and F show brain sections from SJL mice
that received 131I-lymphocytes prepared from SJL mice.
Panels G and H shows brain sections from CD-1 mice that
received 131I-lymphocytes prepared from CD-1 mice.
These results confirm that the radioactivity present in
lymph node and brain tissue was attributable to 131I-
lymphocytes.
Figure 4 shows the distribution of 131I-lymphocytes
among the brain regions in CD-1 male mice. 131I-lym-
phocytes entered all regions of the brain. A statistically
significant difference was noted among the brain regions
by ANOVA: F(22,71) = 3.11, P < 0.005. Newman-Keuls
showed that the olfactory bulb differed from all other
regions including the value for whole brain at P < 0.01.
There were no other statistical differences among the
regions.
Figures 1 and 2 show that 131I-lymphocytes are taken
up differently by the various tissues of the two strains.
We wanted to know whether these differences were
determined predominantly by the lymphocytes, by the
tissues, or by interactions between the lymphocytes and
tissues. We assessed the relative contributions of lym-
phocytes and tissues in determining these uptake pat-
terns, using a 2 × 2 model. The 2 × 2 model was
constructed by injecting 131I-lymphocytes from CD-1
mice into CD-1 or into SJL/J mice and by injecting 131I-
lymphocytes from SJL/J mice into other CD-1 or SJL/J
mice (n = 7/group). A two-way ANOVA was then per-
formed on the four groups with Cells (lymphocytes) and
Mouse (the strain receiving the i.v. injection) being the
independent variables. Statistical significance (P < 0.05)
was used to determine whether an independent variable
had an effect on uptake and the degree of importance of
the variable was indicated by the percentage of variance
it explained. Thirty minutes after injection of the
131I-lymphocytes, the blood and tissues were collected.
For blood, the two-way ANOVA conducted on %Inj/ml
showed an effect of Cells (F(1,23) −5.27, P < 0.05) and
Mouse (F(1,23) = 23.8, P < 0.0001), but not interaction
(Figure 5, upper left panel). Mouse accounted for 46% of
the variance whereas Cells accounted for 10%. These
results show that although both lymphocytes and the tis-
sues had statistically significant influences on 131I-lympho-
cyte clearance from blood, it was the tissues of uptake
rather than the lymphocytes that exerted the predominant
effect.
For brain, two-way ANOVA showed an effect of Cells
(F(1,24) = 13.1, P < 0.005) but no effect of Mouse or
interaction (Figure 5, upper right panel). Cells accounted
for 34% of variance in brain uptake. These results show
that it is the SJL lymphocyte and not the SJL brain that
dictates the greater trafficking of the 131I-lymphocytes
into the CNS.
For spleen (Figure 5, lower left panel), two-way
ANOVA showed an effect for Cells (F(1,24) = 45.7, P <
0.0001), Mouse (F(1,24) = 29.2, P < 0.0001), and inter-
action (F(1,24) = 16.5, P < 0.001). Cells accounted for
40% of the variance, Tissue for 25%, and interaction for
14%. These results are most consistent with the lympho-
cytes having a major independent effect on determining
uptake by spleen, but with the spleen and lymphocyte-
spleen interactions also having effects.
Cervical and axillary nodes did not show any statisti-
cally significant differences attributable to cells or tissue
(Figure 5, lower right panel; results shown only for cer-
vical node). This is consistent with the results shown in
Figure 2, in which the cervical and axillary nodes
showed little or no differences in uptake of 131I-lympho-
cytes between the two strains. The results of the
Newman-Keuls post-test are also shown in the Figure 5
panels (*P < 0.05).
A 2 × 2 study design was used to determine the effects
of the endotoxin LPS on the uptake of lymphocytes in
CD-1 mice (Figure 6). 131I-Lymphocytes from mice trea-
ted with PB or LPS (Cells) were injected into mice trea-
ted with PB or LPS (Mouse, n = 5 to 7/group). No
statistical difference occurred in %Inj/ml (Figure 6,
upper left panel) or for cervical nodes (data not shown).
This suggests that LPS does not affect the net clearance
of 131I-lymphocytes from the blood.
The LPS treatment reduced uptake of 131I-lympho-
cytes into the axillary node and spleen. For axillary
nodes, there was a statistically significant effect only for
Mouse: F(1,20) = 16.1, P < 0.001, which accounted for
Figure 4 Comparison among brain regions of uptake of
131I-lymphocytes in CD-1 mice. The olfactory bulb took up more
131I-lymphocytes than any other region. No other regions, including
whole brain, were statistically different from one another. BR: whole
brain; Olf: olfactory bulb; Stria: striatum; Front: frontal cortex; Parie:
parietal cortex; Hippo: hippocampus; Hypo: hypothalamus; Thal:
thalamus; Occip: occipital cortex; Mid: midbrain; Pons: pons-medulla:
Cereb: cerebellum.
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42% of the variance, but no effect of Cells or interaction
(Figure 6, upper right panel). Spleen also showed a sig-
nificant effect only for Mouse: F(1,21) = 72.4, P <
0.0001, which accounted for 72% of the variance, with
no effect of Cells or interaction (Figure 6, lower left
panel). These results show that for axillary lymph node
and splenic uptake, the effects of LPS on the tissue beds
was the major factor in affecting 131I-lymphocyte uptake.
The LPS treatment greatly increased the uptake of
131I-lymphocytes into brain (Figure 6, lower right panel).
The two-way ANOVA showed an effect of Cells
(F(1,19) = 51.6, P < 0.0001), Mouse (F(1,19) = 17.9, P <
0.001), and interaction (F(1,19) = 12.1, P < 0.01); Cells
accounted for 51% of the variance, Tissue for 18%, and
interaction for 12%. The most consistent explanation for
these results is that although brain, lymphocytes, and
brain-lymphocyte interactions all play a measurable role
in the LPS-induced increase in lymphocyte trafficking
into brain, it is the lymphocyte that is the main deter-
minant. The results for the Newman-Keuls post-test are
shown in the Figure 6 panels (*P < 0.05; **P < 0.01).
Discussion
These experiments applied a pharmacokinetic approach
to examining the trafficking of immune cells across the
BBB and into the CNS with comparison to uptake by
spleen, cervical lymph nodes, and axillary lymph nodes.
We validated the method by several techniques. These
included examination by autoradiography with immuno-
histochemistry of the radioactivity taken up by the brain
Figure 5 Comparison of 131I-lymphocyte tissue uptake in SJL female and CD-1 male mice. A 2 × 2 design was used where lymphocytes
from the cervical lymph nodes of SJL mice were injected into either CD-1 or SJL mice and lymphocytes from the cervical lymph nodes of CD-1
mice were injected into SJL or CD-1 mice. Upper right panel shows that SJL mice tended to have higher levels in the circulation of cells,
regardless of source. Consistent with this, Cells (lymphocytes) accounted for only 10% of statistical variance, whereas the Mouse (tissues of
uptake) accounted for 46%. Upper right panel shows higher uptake of Cells from either source into brain; statistical analysis showed that Cells
accounted for 31% of variance. Lower left panel shows that Cells accounted for 40% of the statistical variance whereas Mouse accounted for 14%.
Lower right panel shows uptake by cervical lymph nodes; there were not statistical differences among the four groups.
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and cervical lymph nodes (Figure 3). To rule out the
possibility that radioactivity in the brain or in the circu-
lation had become detached from the lymphocytes, we
used processing controls to show that the majority of
radioactivity was deposited in the RBC and brain pellet
and not in the supernatant (87% for the RBC pellet and
89% for brain), consistent with the radioactivity being
attached to a cell. We also used capillary depletion to
confirm that lymphocytes taken up by the CNS were
recovered from the parenchyma and were not adhering
to brain capillaries. Immune cells undergo a series of
interactions with the brain endothelial cell in the process
of entering the brain, including rolling or capture, arrest
or firm adhesion, crawling, and diapedesis [10]. Loosely
adhering lymphocytes would have been removed in the
initial washout phase of this procedure and more tightly
adhering lymphocytes and those engaged in diapedesis
would have segregated in the capillary fraction. Under
the conditions of the current experiment, about 80% of
the 131I-lymphocytes detected in brain had crossed the
BBB completely to enter the brain neuropile.
In CD-1 mice, we found that a small percentage of the
immune cells crossed the BBB. The value averaged about
0.02%Inj/g, or about one cell in every 5,000 that was
injected. Given that the typical CD-1 mouse has about
6,000 lymphocytes/μl of whole blood, a hematocrit of
Figure 6 Uptake of 131I-lymphocytes in mice treated with LPS. A 2 × 2 design was used, in which cervical-node lymphocytes from
LPS-treated or phosphate buffer-treated (PB) mice were harvested, radioactively labeled, and injected i.v. into mice that were treated with LPS or
into untreated mice. Upper left hand panel found no difference in levels of 131I-lymphocytes in the circulation. Upper right panel shows control
mice took up more 131I-lymphocytes than did LPS-treated mice, with Mouse accounting for 42% of the statistical variance; these results show that
it was the axillary node rather than the lymphocyte that dominated in determining the degree of uptake. Lower left panel shows similar results
for spleen, with Mouse accounting for 72% of the variance. Lower right panel shows that LPS cells were taken up to a higher degree by brain.
Statistical analysis showed that Cells accounted for 51% of variance, whereas Mouse accounted for 18% and interaction accounted for 12%.
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about 40% [21], and here a brain/RBC ratio of 10 μl/g
for lymphocytes, we calculated a concentration of about
150,000 lymphocytes per g of brain or, given a brain
weight of about 0.45 g, about 67,000 lymphocytes per
whole mouse brain. Lymphocyte uptake by brain was
readily evident at the first time point of 5 min, and rap-
idly reached a steady state. This quantifies the low level
of trafficking across the BBB that many have postulated
is occurring normally. This rate is too low to qualify im-
mune cells as ‘flow dependent’; thus, this work suggests
that immune cell trafficking into brain would be inde-
pendent of the rate of cerebral blood flow [22-24].
Uptake was uniform throughout the brain with the ex-
ception of the olfactory bulb, which had an uptake about
twice that of the other regions. This may reflect an
increased immune surveillance of the olfactory bulb, the
brain region most exposed to the outside environment
owing to its projection as the olfactory nerve through
the cribriform plate, a projection that molecules and
pathogens can use as a pathway into the brain [25-27].
Trafficking into brain was higher in female SJL mice
than in male CD-1 mice, regardless of whether results
were expressed as %Inj/g-brain or as brain/RBC ratios.
Immune cell trafficking can be more readily invoked in
SJL female mice than in male SJL mice or other strains
by the induction of experimental allergic encephalomy-
elitis (EAE), which is used as a model of multiple scler-
osis and to study immune cell crossing of the BBB [28].
Therefore, we chose to compare the male CD-1, a com-
monly used strain of mouse for general studies, with the
female SJL, the strain specially used for study of EAE
and immune cell trafficking into brain, even though it
introduced sex as a confounder. We found that naïve or
untreated SJL female mice had a trafficking rate about 2
to 3 times higher than CD-1 males. The factors that pre-
dispose the SJL strains to the development of EAE are
not altogether clear. Our current findings show that the
SJL mouse has a predisposition to increased trafficking
of immune cells into brain even in the absence of induc-
tion of EAE. This suggests that the induction process
may work by accentuating processes that are already
ongoing in the SJL mouse.
SJL and CD-1 mice also differed in the clearance rate
of immune cells from blood. The CD-1 mice had a
measurable clearance of 131I-lymphocytes from blood
with a half-life of 171 min. In comparison, the SJL
mouse did not show net clearance 131I-lymphocytes
from blood. One explanation for these differences is that
the exchange of 131I-lymphocytes between blood and tis-
sues was at a steady state in the SJL mice, whereas with
time an increasing number of 131I-lymphocytes entered
the tissue beds in the CD-1 mice. For both strains, the
calculated value at t = 0 was about log(0.5)%Inj/ml,
which gives a Vd of about 32 ml. As the vascular space
of these mice is about 2 ml, this shows that the majority
of cells quickly distributed from blood into tissues. This
shows that the vast majority of lymphocytes, about 97% of
them, were in tissue beds rather than circulating. It might
be presumed that much of this uptake was by the spleen
and the lymph nodes. Multiplying the tissue/RBC ratio by
%Inj/ml and dividing by 1,000 yields %Inj/g; multiplying %
Inj/g by tissue weight yields the percentage of the injected
dose contained by that tissue. For example, peak values
for CD-1 spleen ranged from 15 to 20%Inj/g of tissue, a
value about 500 times greater than the uptake rate into
brain (Figure 1, upper panel). Since the spleen weighed, on
average, 123 mg in CD-1 mice, the spleen sequestered
about 2 to 2.5% of the injected lymphocytes. This shows
that although lymphocytes were clearly being sequestered
by the spleen, lymphocytes must have been entering many
other tissues as well.
Because expression of results as %Inj/g of tissue is a
calculation that includes %Inj/ml, we chose to present
subsequent graphic results as tissue/RBC ratios rather
than as %Inj/g of tissue. This is because the differences
that occurred with time between the two strains in %Inj/
ml would automatically bias towards differences in %Inj/
g-tissue.
The spleen/RBC ratio for CD-1 mice was over twice
the value of that for SJL. Thus, whereas the brains of SJL
mice took up more 131I-lymphocytes than the brains of
CD-1 mice, their spleens took up less. Minimal statistical
differences were found for the tissue/RBC ratios between
the strains for uptake by cervical or axillary lymph
nodes. This shows that these two strains of mice differ
in how their lymphocytes traffic into various tissues. It is
also notable that although the lymphocytes were derived
from cervical lymph nodes, their propensity for uptake
by this tissue was no greater than and even less than for
the spleen and axillary lymph nodes.
The differences in 131I-lymphocyte uptake between
strains and among tissues raised the question of whether
these differences were dictated by the lymphocytes or by
the tissues that took them up. It is clear that immune
cell trafficking into peripheral and CNS tissue beds
requires an interactive cross talk between the endothe-
lium and the immune cells [10,14,29]. The responsive-
ness of the brain endothelium is also influenced by cells
behind the BBB, such as microglia and astrocytes [30].
However, whether cells or tissue beds could dominate
under various conditions is a question that is difficult to
address without methods that are temporal and quanti-
tative. We investigated this question with a 2 × 2 experi-
ment, in which cells from SJL or CD-1 mice were
injected into either strain. We used measures of variance
calculated by the two-way ANOVA to determine the
relative influence of lymphocyte, tissue, and lymphocyte-
tissue interactions in determining uptake. Figure 5
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(upper left panel) shows that the %Inj/ml tended to be
higher in SJL mice regardless of lymphocyte source. Stat-
istical analysis confirmed this; although the differences
in clearance from blood were found to be attributable to
both Mouse (in this case, a proxy for clearance of 131I-
lymphocytes from the circulation) and Cells (lympho-
cytes), Mouse accounted for 46% of the variance whereas
Cells accounted for 10%. This argues that it is the per-
ipheral tissues of uptake and not the lymphocytes that
underlie the difference between SJL and CD-1 mice in
clearance rate.
In contrast, lymphocytes from SJL mice entered the
CD-1 and the SJL brain more rapidly than lymphocytes
from CD-1 mice. The statistics confirmed this with only
Cells showing a statistically significant effect; this
demonstrates that it is the lymphocyte, not the brain
and BBB, that primarily dictates the degree of trafficking
into the CNS. For spleen, Cells accounted for 40% of
variance, Mouse for 25%, and the interaction for 14%.
Although SJL lymphocytes were taken up better by the
spleen in both the CD-1 and the SJL mouse, the SJL
mouse spleen took up lymphocytes regardless of source
less readily than the spleen of the CD-1 mouse. In this
case, then, it seems that while the SJL lymphocyte is
more avid in its entry into splenic tissue than the CD-1
lymphocyte, the SJL spleen is less avid than the CD-1
spleen in its uptake of lymphocytes. Thus, both lympho-
cytes and the target tissues contributed to determining
the degree of trafficking, but which of these dominated
varied from case to case. Specifically, it was the periph-
eral tissues that were most important in determining
clearance rate from blood, it was the lymphocytes that
were dominant in determining the degree of uptake into
brain and spleen, and there were no strain effects for up-
take by cervical or axillary lymph nodes.
To test this observation further, that lymphocytes and
tissues interact variably to dictate trafficking, we exam-
ined the effect of LPS in this 2 × 2 modeling design. LPS
did not influence results for the %Inj/ml, suggesting that
LPS does not induce altered clearance of 131I-lympho-
cytes from blood, at least not at the assessed 30 min
time point. LPS did not affect uptake of 131I-lymphocytes
by the cervical node, but LPS had statistically significant
effects on uptake by the axillary node, spleen, and brain.
Thus, the effect of LPS on lymphocyte uptake was tissue
specific. In general, the spleen and axillary nodes of
LPS-treated mice took up fewer lymphocytes (Figure 6,
upper right panel and lower left panel) than those of
non-LPS-treated mice. Consistent with this, the statis-
tical evaluation for axillary lymph nodes and spleen
found an effect for Mouse but not for Cells. In contrast,
lymphocytes from LPS-treated mice had a higher uptake
into brain than lymphocytes from non-LPS-treated mice.
Statistical analysis found that Cells accounted for 51% of
variance for brain uptake, while Mouse accounted for
18% and interaction for 12%. Thus, LPS caused a redis-
tribution of lymphocyte preference by increasing brain
uptake while decreasing splenic and axillary lymph node
uptake. LPS thus affected uptake differently at the vari-
ous tissues, increasing brain uptake by acting primarily
on the lymphocyte, decreasing splenic and axillary
lymph node uptake by acting primarily at those periph-
eral tissues, but having no affect on cervical lymph node
uptake.
Conclusions
In conclusion, we used pharmacokinetic methods and
modeling based on the variance calculations of ANOVA
to quantify trafficking of immune cells obtained from
cervical lymph nodes into brain, spleen, axillary lymph
nodes, and cervical lymph nodes. We found that the
immune cells entered at a low rate into brain and that
such entry occurred to a higher degree in the naïve SJL
female than CD-1 male mice. Treatment with LPS also
increased uptake into brain. Uptake by the immune tis-
sues varied between SJL and CD-1 mice and between
LPS-treated and untreated mice. Both lymphocytes and
tissues influenced the degree to which lymphocytes were
taken up by tissues, but one or the other tended to dom-
inant in determining the degree of uptake. Lymphocyte
characteristics chiefly accounted for increased immune
cell entry into brains of SJL and LPS-treated mice and
the decreased uptake into the spleen of SJL mice,
whereas tissue had the primary influence in the
decreased immune cell uptake by spleen and axillary
nodes in LPS-treated mice.
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